960 x 350_41

ADME / DMPK Services

Developing a potential drug candidate is an iterative process that requires careful planning to reach clinical trials. Most new drug candidates fail during preclinical and clinical development, and identifying those with promising ADME and pharmacokinetics properties during the discovery stage can streamline the development process. Preclinical ADME screening, drug metabolism, and pharmacokinetics assessments focus effort on potentially viable drug candidates, guiding decision-making from early discovery to Investigational New Drug (IND) filing and beyond.


As an industry leader clinical trial laboratory services, Q2 Solutions can help you make informed development decisions about your drug candidates by offering an array of high-throughput ADME screening and DMPK services that use validated bioanalytical methods to support candidate identification and characterization. Our scientists have extensive expertise with high-throughput discovery bioanalysis and LC/MS bioanalysis platforms that enable various aspects of ADME testing and pharmacokinetic (PK) testing. From in vitro ADME screening assays and drug-drug interaction risk assessment to metabolite identification of in vitro and in vivo samples, Q2 Solutions’ services facilitate rapid drug discovery ADME property optimization and regulatory filings.

Our in vitro ADME laboratory can help you save time, reduce costs, and conserve resources in your drug discovery efforts

In vitro Screening

In Vitro screening plays a critical role in drug candidate optimization of ADME properties. Identifying the most promising drug candidates upfront accelerates the development cycle, reduces costs, streamlines the drug discovery pipeline, and guides subsequent pre-clinical and clinical studies. Q2 Solutions’ highly automated in vitro ADME laboratory offers a range of high-throughput ADME screening services to support the lead optimization stage of drug discovery, including assays for metabolic stability, cell permeability, and risk assessment for inhibiting cytochrome P450 enzymes.


To learn more about how Q2 Solutions’ ADME screening bundles and LC/MS bioanalytical capabilities can support your in vitro and pharmacokinetic (PK) testing please visit the links below:


In vitro Metabolism

The ADME assay development pipeline includes in vitro ADME assays that are necessary once a lead candidate has been selected. The safety profile of a drug candidate will depend partly on its interactions with other drugs, especially those that may be administered concomitantly in standard-of-care treatment. Assessing the risks of possible drug-interactions using validated bioanalytical methods is thus an essential early step in the candidate development process. Q² Solutions offers a suite of in vitro assays to support drug-drug interaction testing, including cytochrome P450 (CYP) enzyme inhibition (IC50), time-dependent CYP inhibition, induction of CYP enzymes, and CYP reaction phenotyping. All in vitro metabolism assay results are presented in fully QC-reviewed, regulatory-style reports to support filing of IND applications.

To learn more about how Q2 Solutions’ in vitro assay bundle can inform your drug-drug interaction testing efforts, please follow the link below:


Assessing a Assessing a drug candidate’s metabolic profile early in the discovery process offers insight into its metabolic clearance pathways in both pre-clinical species and humans. Q2 Solutions’ global bioanalytical and ADME laboratory network offers a range of liquid chromatography/ mass spectrometry services to support discovery and development metabolite identification and profiling.
Specific capabilities using high-resolution mass spectrometry (HRMS) include:

  • Metabolite profiling and identification using liver microsomes or hepatocytes, as well as novel hepatocyte co-culture models for profiling slowly metabolized drug candidates
  • Exploratory profiling using unlabeled drug in preclinical and human clinical samples
  • Radio-profiling of both preclinical and human clinical samples
  • Reactive intermediate screens evaluating glutathione/cyanide trapping drug candidates (microsomes)

To explore how Q2 Solutions can partner to characterize metabolites in your study, please follow the link below:

Related Thought Leaders Insights

Hybrid Assays for Protein Bioanalysis

Authors: Steve Lowes, Ph.D., Senior Director, Bioanalytical Services Barry Jones, Ph.D., Director, LC-MS Biologics and Biomarkers Hybrid assays are powerful tools for protein bioanalysis of both...

Quantitative Assays for Peptides using LC-MS

We are one of the few bioanalytical laboratories successfully employing immunoprecipitation techniques, HRMS, and multi-dimensional liquid chromatography for the quantitation of peptide and protein...

Developing Assays for Novel Drugs

Novel drugs with complex design are becoming more common to treat difficult diseases. This insight brief, authored by Michael Brown, Ph.D., Senior Director, Immunoanalytical Services and Barry Jones,...